Ariad Pharmaceuticals Stock Rating Reaffirmed by Citigroup Inc. (ARIA)
Ariad Pharmaceuticals (NASDAQ:ARIA)‘s stock had its “sell” rating reaffirmed by equities research analysts at Citigroup Inc. in a research note issued to investors on Friday. They currently have a $5.00 price target on the stock, down from their previous price target of $7.00. Citigroup Inc.’s price objective indicates a potential downside of 7.58% from the stock’s previous close.
ARIA has been the subject of a number of other recent research reports. Analysts at JMP Securities cut their price target on shares of Ariad Pharmaceuticals from $8.00 to $7.00 in a research note on Thursday. They now have a “market outperform” rating on the stock. Separately, analysts at Chardan Capital reiterated a “buy” rating on shares of Ariad Pharmaceuticals in a research note on Thursday. Finally, analysts at Jefferies Group reiterated a “positive” rating on shares of Ariad Pharmaceuticals in a research note on Monday, June 2nd. Four analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have assigned a buy rating to the company. Ariad Pharmaceuticals has an average rating of “Hold” and a consensus price target of $6.75.
Shares of Ariad Pharmaceuticals (NASDAQ:ARIA) traded up 0.55% during mid-day trading on Friday, hitting $5.44. The stock had a trading volume of 1,437,729 shares. Ariad Pharmaceuticals has a 52-week low of $2.15 and a 52-week high of $23.00. The stock has a 50-day moving average of $5.95 and a 200-day moving average of $7.07. The company’s market cap is $1.014 billion.
Ariad Pharmaceuticals (NASDAQ:ARIA) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.30) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.29) by $0.01. The company had revenue of $12.10 million for the quarter, compared to the consensus estimate of $13.65 million. During the same quarter last year, the company posted ($0.37) earnings per share. Ariad Pharmaceuticals’s revenue was down 13.6% compared to the same quarter last year. Analysts expect that Ariad Pharmaceuticals will post $-1.14 EPS for the current fiscal year.
ARIAD Pharmaceuticals, Inc (NASDAQ:ARIA) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.